HIV and HCV in DC: Epidemic Intricacies and Inclusive Approaches for Substance-Using Populations
Among persons living with HIV in the United States, an estimated 15 to 30% have HCV coinfection. For persons living with HIV who have HCV coinfection, liver-related morbidity and mortality is a prominent non-AIDS-related complication—up to 80 to 90% of liver-related deaths in persons living with HIV are attributable to HCV infection-and proper treatment remains a priority. This webinar will discuss HIV/HCV co-infection in DC, particularly among people who inject drugs, and evidence-based prevention and treatment strategies.
Learning Objectives
After completing this activity, the participant should be better able to:
- Discuss the epidemiology of HIV and HCV infections in populations of people who use drugs, in the District of Columbia.
- Outline established and emerging strategies to prevent infection in these individuals.
- Evaluate the approach to treatment of HIV and HCV in these individuals.
Other Related Trainings
Beyond the Basics: Navigating the HIV-Cancer Intersection
This webinar will shed light on the reasons behind increased risk of certain cancers among people living with HIV and why their cancer outcomes are worse compared to people without HIV. The faculty will delve into evidence-based strategies to improve survival in HIV-associated cancers. The webinar also will cover potential treatment options that may exploit unique characteristics of these cancers to improve outcomes.
HIV and Older Adults: Managing Chronic Disease and Polypharmacy
This webinar will focus on the unique healthcare needs of older adults living with HIV. Faculty will explore the challenges of managing multiple chronic conditions alongside HIV, as well as the complexities of using multiple medications, known as polypharmacy. The session will review strategies for optimizing care, minimizing drug interactions, and improving overall health outcomes in this growing population.
